SCHEMBL259634

SCHEMBL259634

COc1c(C)cc(C)cc1[P@](CC[P@](c1ccccc1)c1cc(C)cc(C)c1OC)c1ccccc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.37
▸ L3MBTL1 Q9Y468 3/20 0.37
▸ LMNA P02545 2/20 0.35
▸ HTT P42858 1/20 0.33
▸ ACHE P22303 1/20 0.32
▸ HTR2A P28223 4/20 0.32
▸ HTR7 P34969 4/20 0.32
▸ PDE4A P27815 1/20 0.31
▸ PDE4B Q07343 1/20 0.31
▸ PDE4C Q08493 1/20 0.31
▸ PDE4D Q08499 1/20 0.31
▸ MEN1 O00255 1/20 0.31
▸ KMT2A Q03164 1/20 0.31
▸ ATM Q13315 1/20 0.31
▸ MAPK1 P28482 2/20 0.31
▸ HPGD P15428 1/20 0.31
▸ SLC6A2 P23975 1/20 0.31
▸ SLC6A4 P31645 1/20 0.31
▸ SLC6A3 Q01959 1/20 0.31
▸ KDM4E B2RXH2 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14050885 0.86 MAPT (0.31) MAPTL3MBTL1LMNA
SCHEMBL259633 0.81 POLB (0.33) MAPTMAPK1KDM4EALDH1A1SMN1; SMN2
SCHEMBL258728 0.79 MAPT (0.35) MAPTL3MBTL1LMNAHTTACHE
SCHEMBL258715 0.79 MAPT (0.35) MAPTL3MBTL1LMNAHTTACHE
SCHEMBL10961316 0.73 ACHE (0.44) MAPTL3MBTL1LMNAHTTACHE
SCHEMBL16488059 0.72 ACHE (0.44) MAPTL3MBTL1LMNAACHEMEN1
SCHEMBL4885181 0.70 ACHE (0.38) MAPTLMNAHTTACHEALDH1A1
SCHEMBL10259028 0.70 ACHE (0.38) MAPTLMNAHTTACHEALDH1A1
SCHEMBL20021638 0.70 CA1 (0.38) MAPTLMNAMEN1KMT2AATM
SCHEMBL20906761 0.70 KDM4E (0.31) MAPK1KDM4EALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8067642-B2 Chiral phosphorous compounds Celtice Catalysts Limited, Nova UCD (IE) 2011-11-29 — — US disclosed
US-8067642-B2 Chiral phosphorous compounds Celtice Catalysts Limited, Nova UCD (IE) 2011-11-29 — — US disclosed
US-20100168456-A1 CHIRAL PHOSPHOROUS COMPOUNDS CELTIC CATALYSTS LIMITED (IE) 2010-07-01 — — US disclosed
US-20100168456-A1 CHIRAL PHOSPHOROUS COMPOUNDS CELTIC CATALYSTS LIMITED (IE) 2010-07-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168456-A1 CHIRAL PHOSPHOROUS COMPOUNDS RPP30, PLCB3, INPP5D MAPT 4587/4885L3MBTL1 2556/4885LMNA 4020/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback